OBJECTIVES: To evaluate the association between improvements in clinical and patient-reported outcomes (PROs) and improvements in workplace and household productivity in psoriatic arthritis (PsA) patients treated with certolizumab pegol (CZP). METHODS: Analyses used Week (Wk) 24 data from the double-blind, placebo-controlled period of RAPID-PsA (NCT01087788), for patients originally randomized to CZP. Responders and non-responders for clinical outcomes and PROs were compared in terms of change from baseline (CFB) in workplace and household productivity, assessed with the arthritis-specific Work Productivity Survey (WPS). Groups were compared using a non-parametric bootstrap-t method. LOCF was used for WPS outcomes; NRI for clinical outcomes and PRO MCIDs. RESULTS: CONCLUSIONS: Achievement of disease remission, clinically meaningful improvements in joint and skin outcomes and symptom relief were associated with increased workplace and household productivity in PsA patients treated with CZP.